Spyre Therapeutics, Inc.
SYRE
$15.18
$0.644.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.64% | 38.60% | 27.01% | 31.76% | -368.15% |
| Total Depreciation and Amortization | -- | -- | -100.00% | -100.00% | -79.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -81.19% | -77.32% | -61.59% | -67.23% | 3,665.20% |
| Change in Net Operating Assets | -2,223.85% | 12.91% | -282.03% | -874.87% | 84.99% |
| Cash from Operations | -53.28% | -57.55% | -73.82% | -131.79% | -54.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -100.00% | -- |
| Cash Acquisitions | -- | -- | -100.00% | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.87% | -215.71% | -248.09% | -795.89% | -578.81% |
| Cash from Investing | -7.48% | -225.93% | -268.76% | -751.50% | -571.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 96.85% |
| Issuance of Common Stock | 168.48% | 187.07% | 83,477.24% | 498,938.89% | 107.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -42.56% | 20.84% | 20.84% | -- |
| Repurchase of Preferred Stock | 97.19% | 97.19% | 97.19% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 91.45% | 68.25% | -- | -- | -- |
| Cash from Financing | -55.20% | 13.80% | 76.70% | 54.20% | 1,149.49% |
| Foreign Exchange rate Adjustments | -90.00% | -112.00% | -43.40% | -123.08% | 113.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.76% | -165.31% | -139.55% | -196.86% | 852.40% |